If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEPATOLOGY<br /> AASLD supplement • emjreviews.com<br /> INSIDE<br /> The Liver<br /> Meeting 2014<br /> THE LIVER MEETING 2014:<br /> Summary of presentations from the 65th Annual Liver Meeting<br /> of the American Association for the Study of Liver Diseases<br /> (AASLD), held in Boston, Massachusetts, USA,<br /> on 7th-11th November 2014<br /> Nezam Hassan Afdhal,1 Graham Foster,2 *Jean-Michel Pawlotsky3,4<br /> 1. Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center,<br /> Harvard Medical School, Boston, Massachusetts, USA<br /> 2. Queen Mary University of London, Institute of Cell and Molecular Science, London, UK<br /> 3. National Reference Center for Viral Hepatitis B, C and D, Department of Virology,<br /> Hôpital Henri Mondor, Université Paris-Est, Créteil, France<br /> <a title="EMJ Hepatol. 2015 Suppl 3 page 1" href="http://viewer.zmags.com/publication/e8b9d2fc?page=1"> HEPATOLOGY AASLD supplement • emjreviews.com I</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 2" href="http://viewer.zmags.com/publication/e8b9d2fc?page=2"> THE LIVER MEETING 2014: Summary of presentations </a> <a title="EMJ Hepatol. 2015 Suppl 3 page 3" href="http://viewer.zmags.com/publication/e8b9d2fc?page=3"> Table 1: Key clinical data presented at the Ameri</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 4" href="http://viewer.zmags.com/publication/e8b9d2fc?page=4"> Table 1 continued. GT Patient characteristics Pre</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 5" href="http://viewer.zmags.com/publication/e8b9d2fc?page=5"> patients, except for treatment-naïve GT3 patients</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 6" href="http://viewer.zmags.com/publication/e8b9d2fc?page=6"> Table 3 continued. Study Treatment arms/subgr</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 7" href="http://viewer.zmags.com/publication/e8b9d2fc?page=7"> Daclatasvir + Sofosbuvir DCV is the first-in-class</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 8" href="http://viewer.zmags.com/publication/e8b9d2fc?page=8"> Table 4 continued. Study Treatment arms/subgr</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 9" href="http://viewer.zmags.com/publication/e8b9d2fc?page=9"> Table 4 continued. Study Treatment arms/subgr</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 10" href="http://viewer.zmags.com/publication/e8b9d2fc?page=10"> Table 4 continued. Study Treatment arms/subgr</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 11" href="http://viewer.zmags.com/publication/e8b9d2fc?page=11"> treated with SOF+RBV and SOF+RBV+pegINF, resp</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 12" href="http://viewer.zmags.com/publication/e8b9d2fc?page=12"> Table 5: Key results from studies presented at th</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 13" href="http://viewer.zmags.com/publication/e8b9d2fc?page=13"> for end-stage liver disease and CPT scores </a> <a title="EMJ Hepatol. 2015 Suppl 3 page 14" href="http://viewer.zmags.com/publication/e8b9d2fc?page=14"> Table 6 continued. Study Treatment arms/ subgroup</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 15" href="http://viewer.zmags.com/publication/e8b9d2fc?page=15"> was evaluated across three cohorts consistin</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 16" href="http://viewer.zmags.com/publication/e8b9d2fc?page=16"> Genotype 3 Non-cirrhotic/treatment-naïve patients</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 17" href="http://viewer.zmags.com/publication/e8b9d2fc?page=17"> Phase III SAPPHIRE-I, SAPPHIRE-II, TURQUOISE- II,</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 18" href="http://viewer.zmags.com/publication/e8b9d2fc?page=18"> were observed regardless of RBV combination or tr</a> <a title="EMJ Hepatol. 2015 Suppl 3 page 19" href="http://viewer.zmags.com/publication/e8b9d2fc?page=19"> Association for the Study of Liver Diseases (AASL</a>